Bernstein Weighs In on Bristol-Myers Squibb (BMY) Ahead of H2 Critical Clinical Readouts
Tweet Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $58.00 price target on Bristol-Myers Squibb Co. (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
